Items

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, US National Library of Medicine National Institutes of Health, pp. 100 - 101, Sep, 2016

• Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial (2019-06)

  S. Cheol Shim, LJ. Božić, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, F. G Medina-Rodriguez, P. Miranda, P. Shesternya, J. Chavez-Corrales, P. Wiland, S. Jeka, O. Garmish, P. Hrycaj, N. Fomina, W. Park, C. Hee Suh, S. Joon Lee, S. Young Lee, Y. Ju Bae, D. Hyun Yoo, Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial, RHEUMATOLOGY, pp. 2193 - 2202, Jun, 2019